The relevance of antiphospholipid antibodies in obstetrics

1. McIntyre JA, Wagenknecht DR, Sugi T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection – an overview. Am J Reprod Immunol 1997; 37 (1): 101–110. doi: 10.1111/j.1600-0897.1997.tb00198.x.

2. Devreese KM, de Groot PG, de Laat B et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11): 2828–2839. doi: 10.1111/jth.15047.

3. Tripodi A. Diagnostic challenges on the laboratory detection of lupus anticoagulant. Biomedicines 2021; 9 (7): 844. doi: 10.3390/bio- medicines9070844.

4. Oztürk MA, Haznedaroğlu IC, Turgut M et al. Current debates in antiphospholipid syndrome: the acquired antibody-mediated thrombophilia. Clin Appl Thromb Hemost 2004; 10 (2): 89–126. doi: 10.1177/107602960401000201.

5. McDonnell T, Wincup C, Buchholz I et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS. Blood Rev 2020; 39: 100610. doi: 10.1016/j.blre.2019.100610.

6. Hulstein JJ, Lenting PJ, de Laat B et al. beta2--Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110 (5): 1483–1491. doi: 10.1182/blood-2006-10-053199.

7. Devignes J, Smaïl-Tabbone M, Hervé A et al. Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: association with baseline antiphospholipid antibodies titres. Int J Lab Hematol 2019; 41 (6): 726–730. doi: 10.1111/ijlh.13094.

8. El Hasbani G, Viola M, Sciascia S et al. Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence. Rheumatol Ther 2021; 8 (1): 81–94. doi: 10.1007/s40744-020-00273-w.

9. Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol 2007; 32 (2): 184–187. doi: 10.1007/s120 16-007-0003-1.

10. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62 (5): 388–393. doi: 10.1136/ard.62.5.388.

11. Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep 2012; 14 (1): 71–78. doi: 10.1007/s11926-011-0227-1.

12. Di Prima FA, Valenti O, Hyseni E et al. Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med 2011; 5 (2): 41–53.

13. Duarte-García A, Pham MM, Crowson CS et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019; 71 (9): 1545–1552. doi: 10.1002/art.40901.

14. Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S et al. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep 2022; 23 (12): 85. doi: 10.1007/s11926021-01038-2.

15. Rahman A, Raimondo MG. Secondary Antiphospholipid Syndrome. In: Meroni P (ed). Antiphospholipid Antibody Syndrome. Rare Diseases of the Immune System. Cham: Springer 2015: 233–248.

16. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2): 295–306. doi: 10.1111/j.1538-7836.2006.01753.x.

17. Brandt JT, Triplett DA, Alving B et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74 (4): 1185–1190.

18. The American College of Rheumatology, The European Alliance of Associations for Rheumatology. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023; 82 (10): 1258–1270. doi: 10.1136/ard-2023-224609.

19. Asherson RA, Cervera R, de Groot PG et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12 (7): 530–534. doi: 10.1191/096120 3303lu394oa.

20. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010; 9 (5): A299–A304. doi: 10.1016/j.autrev.2009.11.013.

21. Sammaritano LR, Bonnie LB, Chakravarty EE et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72 (4): 529–556. doi: 10.1002/art.41191.

22. Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10): 1296–1304. doi: 10.1136/annrheumdis-2019-215213.

23. Meroni PL, Borghi MO, Grossi C et al. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? Nat Rev Rheumatol 2018; 14 (7): 433–440. doi: 10.1038/ s41584-018-0032-6.

24. Bramham K, Hunt BJ, Germain S et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19 (1): 58–64. doi: 10.1177/0961203309347 794.

25. Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev 2015; 14 (5): 446–471. doi: 10.1016/j.autrev.2015.01.008.

26. Poulton K, Ripoll VM, Pericleous C et al. Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol 2015; 73 (5): 390–401. doi: 10.1111/aji.12 341.

27. Kelchtermans H, Pelkmans L, de Laat B et al. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost 2016; 14 (8): 1530–1548. doi: 10.1111/jth. 13379.

28. Chayoua W, Kelchtermans H, Gris JC et al. The (non-) sense of detecting anti-cardiolipin and anti-b2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 2020; 18 (1): 169–179. doi: 10.1111/jth.14 633.

29. Pregnolato F, Gerosa M, Raimondo MG et al. EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology (Oxford) 2021; 60 (3): 1114–1124. doi: 10.1093/rheumatology/keaa203.

30. Anunciación-Llunell A, Muñoz C, Roggenbuck D et al. Differences in antiphospholipid antibody profile between patients with obstetric and thrombotic antiphospholipid syndrome. Int J Mol Sci 2022; 23 (21): 12819. doi: 10.3390/ijms232112819.

31. Yelnik CM, Laskin CA, Porter TF et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3 (1): e000131. doi: 10.1136/lupus-2015-000131.

32. Saccone G, Berghella V, Maruotti GM et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 2017; 216 (5): 525.e1–525.e12. doi: 10.1016/j.ajog.2017.01.026.

33. Otomo K, Atsumi T, Amengual O et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64 (2): 504–512. doi: 10.1002/art. 33340.

34. Sciascia S, Sanna G, Murru V et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013; 52 (8): 1397–1403. doi: 10.1093/rheumatology/kes388.

35. Del Barrio-Longarela S, Martínez-Taboada VM, Blanco-Olavarri P et al. Does adjusted Global Antiphospholipid Syndrome Score (aGAPSS) predict the obstetric outcome in antiphospholipid antibody carriers? A single-center study. Clin Rev Allergy Immunol 2022; 63 (2): 297–310. doi: 10.1007/s12016-021-08 915-9.

36. Pires da Rosa G, Bettencourt P, Rodríguez--Pintó I et al. “Non-criteria” antiphospholipid syndrome: a nomenclature proposal. Autoimmun Rev 2020; 19 (12): 102689. doi: 10.1016/j.autrev. 2020.102689.

37. Martínez-Taboada VM, Blanco-Olavarri P, Del Barrio-Longarela S et al. Non-criteria obstetric antiphospholipid syndrome: how different is from Sidney criteria? A single-center study. Biomedicines 2022; 10 (11): 2938. doi: 10.3390/biomedicines10112938.

38. Conti F, Andreoli L, Crisafulli F et al. Does seronegative obstetric APS exist? “pro” and “cons”. Autoimmun Rev 2019; 18 (12): 102407. doi: 10.1016/j.autrev.2019.102407.

39. Chighizola CB, Raimondo MG, Comerio C et al. The risk of obstetric complications and the effects of treatment in women with low titer and medium-high titer anti-phospholipid antibodies. Arthritis Rheumatol 2016; 68 (S10): Abstract 1074.

40. Yelnik CM, Porter TF, Branch DW et al. Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. Arthritis Rheumatol 2016; 68 (8): 1964–1969. doi: 10.1002/art.39668.

41. Pignatelli P, Ettorre E, Menichelli D et al. Seronegative antiphospholipid syndrome: refining the value of „non-criteria” antibodies for diagnosis and clinical management. Haematologica 2020; 105 (3): 562–572. doi: 10.3324/ haematol.2019.221945.

42. Mekinian A, Bourrienne MC, Carbillon L et al. Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and treatment efficacy in pregnancies. Semin Arthritis Rheum 2016; 46 (2): 232–237. doi: 10.1016/j.semarthrit.2016.05.006.

43. Hamulyák EN, Scheres LJ, Marijnen MC et al. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev 2020; 5 (5): CD012852. doi: 10.1002/14651858.CD012852.pub2.

44. Fierro JJ, Velásquez-Berrío M, Ospina A et al. The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome. Rheumatol Int 2024; 44 (2): 223–234. doi: 10.1007/s00296-023-054 57-5.

45. Albert CR, Schlesinger WJ, Viall CA et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 2014; 71 (2): 154–164. doi: 10.1111/aji.12 184.

46. Tian Y, Xu J, Chen D et al. The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: a systematic review and meta-analysis. J Gynecol Obstet Hum Reprod 2021; 50 (8): 102121. doi: 10.1016/j.jogoh.2021.102121.

47. Schreiber K, Breen K, Cohen H et al. Hydroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017; 43 (6): 562–571. doi: 10.1055/s-0037-1603359.

48. Belizna C, Pregnolato F, Abad S et al. HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev 2018; 17 (12): 1153–1168. doi: 10.1016/j.autrev.2018.05.012.

49. Mekinian A, Vicaut E, Cohen J et al. Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL. Gynecol Obstet Fertil Senol 2018; 46 (7–8): 598–604. doi: 10.1016/j.gofs.2018.06.008.

50. Cáliz RC, Del Campo Fontecha PD, Izquierdo MG et al. Recommendations of the Spanish rheumatology society for primary antiphospholipid syndrome. Part II: obstetric antiphospholipid syndrome and special situations. Reumatol Clin (Engl Ed) 2020; 16 (2 Pt 2): 133–148. doi: 10.1016/j.reuma.2018.11.004

51. Lefkou E, Mamopoulos A, Dagklis T et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest 2016; 126 (8): 2933–2940. doi: 10.1172/JCI86 957.

52. Lockwood CJ, Lockshin MD. Antiphospholipid syndrome: obstetric implications and management in pregnancy. In: Post T (ed). UpToDate. Waltham, Mass.: UpToDate 2023 [online]. Available from: www.uptodate.com.

53. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev 2019; 18 (4): 406–414. doi: 10.1016/j.autrev.2018.12.006.